After DEA floats telehealth prescribing rule, experts say it needs work

Why This Topic Matters

The proposal could affect how practices document, register, and manage telehealth prescribing workflows for controlled substances. Understanding the rule’s scope and stakeholder concerns helps organizations assess compliance burden, patient access implications, and whether to submit a comment.

Article Sections

1. Telehealth

   Introduces the DEA proposal in the context of telehealth prescribing and the post-PHE policy environment. It sets up the article’s focus on the rule’s scope and timing.

2. Experts predict administrative burden, patient impact

   Summarizes expert concerns about operational complexity, registration structure, monitoring expectations, and possible effects on access to care. The section highlights why stakeholders view parts of the proposal as difficult to implement.

3. Look for statements you can use

   Explains the public comment opportunity and notes that stakeholder groups plan to share draft comments and advocacy materials. It also identifies the general organizations involved in the response process.

4. Resource

   Provides a reference to the public rulemaking docket and comment portal. The section serves as the article’s source link for readers seeking the official proposal.